Donepezil placebo

DRUG5 trials

Sponsors

AstraZeneca, Takeda, Tetra Discovery Partners, Mediforum Ltd., Co.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseHealthy VolunteersMemory ImpairmentMild Alzheimer Disease

Phase 1

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

CompletedNCT02051335

AstraZenecaAlzheimer's Disease, Memory Impairment

Start: 2014-01-31End: 2014-05-31Updated: 2017-02-01

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

TerminatedNCT02769065

TakedaAlzheimer Disease, Healthy Volunteers

Start: 2016-05-05End: 2017-06-08Updated: 2019-06-10

TAK-071 Scopolamine-Induced Cognitive Impairment Study

TerminatedNCT02918266

TakedaHealthy Volunteers

Start: 2016-11-21End: 2017-08-08Updated: 2019-06-14

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

CompletedNCT03030105

Tetra Discovery PartnersAlzheimer Disease

Start: 2017-01-31End: 2017-06-30Updated: 2018-10-16

Phase 2

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease

Mediforum Ltd., Co.Mild Alzheimer Disease

Start: 2020-11-27End: 2024-08-13Target: 312Updated: 2023-04-18

Related Papers

[P2–051]: <i>IN VITRO</i> CHARACTERIZATION OF TAK‐071: A NOVEL MUSCARINIC M<sub>1</sub> RECEPTOR‐POSITIVE ALLOSTERIC MODULATOR WITH LOW COOPERATIVITY

Alzheimer s & Dementia2017-07-012 citations

[P2–048]: AN APPROACH TO DISCOVER NOVEL MUSCARINIC M<sub>1</sub> RECEPTOR‐POSITIVE ALLOSTERIC MODULATORS WITH POTENT COGNITIVE IMPROVEMENT AND MINIMIZED GASTROINTESTINAL DYSFUNCTION

Alzheimer s & Dementia2017-07-011 citations